188 related articles for article (PubMed ID: 35910942)
1. Managing surgery in hemophilia with recombinant factor VIII Fc and factor IX Fc: Data on safety and effectiveness from phase 3 pivotal studies.
Chowdary P; Holmström M; Mahlangu JN; Ozelo MC; Pabinger I; Pasi KJ; Ragni MV; Shapiro A; Barnowski C; Lethagen S
Res Pract Thromb Haemost; 2022 Jul; 6(5):e12760. PubMed ID: 35910942
[TBL] [Abstract][Full Text] [Related]
2. Recombinant factor IX Fc for major surgery in hemophilia B: factor IX plasma activity levels and effective hemostasis.
Shapiro AD; Chambost H; Ozelo MC; Falk A; Ahlin H; Casiano S; Santagostino E
Res Pract Thromb Haemost; 2023 Aug; 7(6):102169. PubMed ID: 37694269
[TBL] [Abstract][Full Text] [Related]
3. Surgical outcomes in patients with haemophilia A or B receiving extended half-life recombinant factor VIII and IX Fc fusion proteins: Real-world experience in the Nordic countries.
Lehtinen AE; Baghaei F; Astermark J; Holme PA
Haemophilia; 2022 Sep; 28(5):713-719. PubMed ID: 35575446
[TBL] [Abstract][Full Text] [Related]
4. Long-term outcomes of prophylaxis with a recombinant factor VIII Fc or recombinant factor IX Fc in patients with hemophilia previously treated on demand.
Álvarez-Román MT; Shapiro AD; Ragni MV; Palmborg H; Bystrická L; Szamosi J; Casiano S; Chambost H
Res Pract Thromb Haemost; 2023 Aug; 7(6):102163. PubMed ID: 37720484
[TBL] [Abstract][Full Text] [Related]
5. Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A.
Mahlangu JN; Ragni M; Gupta N; Rangarajan S; Klamroth R; Oldenburg J; Nogami K; Young G; Cristiano LM; Dong Y; Allen G; Pierce GF; Robinson B
Thromb Haemost; 2016 Jul; 116(1):1-8. PubMed ID: 26962852
[TBL] [Abstract][Full Text] [Related]
6. Long-term safety and efficacy of extended-interval prophylaxis with recombinant factor IX Fc fusion protein (rFIXFc) in subjects with haemophilia B.
Pasi KJ; Fischer K; Ragni M; Nolan B; Perry DJ; Kulkarni R; Ozelo M; Mahlangu J; Shapiro AD; Baker RI; Bennett CM; Barnes C; Oldenburg J; Matsushita T; Yuan H; Ramirez-Santiago A; Pierce GF; Allen G; Mei B
Thromb Haemost; 2017 Feb; 117(3):508-518. PubMed ID: 28004057
[TBL] [Abstract][Full Text] [Related]
7. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B.
Powell JS; Pasi KJ; Ragni MV; Ozelo MC; Valentino LA; Mahlangu JN; Josephson NC; Perry D; Manco-Johnson MJ; Apte S; Baker RI; Chan GC; Novitzky N; Wong RS; Krassova S; Allen G; Jiang H; Innes A; Li S; Cristiano LM; Goyal J; Sommer JM; Dumont JA; Nugent K; Vigliani G; Brennan A; Luk A; Pierce GF;
N Engl J Med; 2013 Dec; 369(24):2313-23. PubMed ID: 24304002
[TBL] [Abstract][Full Text] [Related]
8. Long-acting recombinant factor IX Fc fusion protein (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B-LONG study.
Powell JS; Apte S; Chambost H; Hermans C; Jackson S; Josephson NC; Mahlangu JN; Ozelo MC; Peerlinck K; Pasi J; Perry D; Ragni MV; Wang X; Jiang H; Li S; Cristiano LM; Innes A; Nugent K; Brennan A; Luk A; Allen G; Pierce GF; Robinson B
Br J Haematol; 2015 Jan; 168(1):124-34. PubMed ID: 25208598
[TBL] [Abstract][Full Text] [Related]
9. Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A.
Young G; Mahlangu J; Kulkarni R; Nolan B; Liesner R; Pasi J; Barnes C; Neelakantan S; Gambino G; Cristiano LM; Pierce GF; Allen G
J Thromb Haemost; 2015 Jun; 13(6):967-77. PubMed ID: 25912075
[TBL] [Abstract][Full Text] [Related]
10. Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels.
Shapiro AD; Ragni MV; Kulkarni R; Oldenberg J; Srivastava A; Quon DV; Pasi KJ; Hanabusa H; Pabinger I; Mahlangu J; Fogarty P; Lillicrap D; Kulke S; Potts J; Neelakantan S; Nestorov I; Li S; Dumont JA; Jiang H; Brennan A; Pierce GF
J Thromb Haemost; 2014 Nov; 12(11):1788-800. PubMed ID: 25196897
[TBL] [Abstract][Full Text] [Related]
11. Long-term safety and sustained efficacy for up to 5 years of treatment with recombinant factor IX Fc fusion protein in subjects with haemophilia B: Results from the B-YOND extension study.
Pasi KJ; Fischer K; Ragni M; Kulkarni R; Ozelo MC; Mahlangu J; Shapiro A; P'Ng S; Chambost H; Nolan B; Bennett C; Matsushita T; Winding B; Fruebis J; Yuan H; Rudin D; Oldenburg J
Haemophilia; 2020 Nov; 26(6):e262-e271. PubMed ID: 32497409
[TBL] [Abstract][Full Text] [Related]
12. Post hoc longitudinal assessment of the efficacy and safety of recombinant factor IX Fc fusion protein in hemophilia B.
Shapiro AD; Kulkarni R; Ragni MV; Chambost H; Mahlangu J; Oldenburg J; Nolan B; Ozelo MC; Foster MC; Willemze A; Barnowski C; Jain N; Winding B; Dumont J; Lethagen S; Barnes C; Pasi KJ
Blood Adv; 2023 Jul; 7(13):3049-3057. PubMed ID: 36848635
[TBL] [Abstract][Full Text] [Related]
13. Physical activity and bleeding outcomes among people with severe hemophilia on extended half-life or conventional recombinant factors.
Shrestha A; Su J; Li N; Barnowski C; Jain N; Everson K; Jena AB; Batt K
Res Pract Thromb Haemost; 2021 Jan; 5(1):94-103. PubMed ID: 33537533
[TBL] [Abstract][Full Text] [Related]
14. Recombinant factor IX Fc prophylaxis reduces pain and increases levels of physical activity, with sustained, long-term improvements in patients with hemophilia B:
Astermark J; Hermans C; Ezzalfani M; Sidhom A; Barbier S; Kragh N; Falk A; Eriksson D
Ther Adv Hematol; 2023; 14():20406207231170701. PubMed ID: 37283819
[TBL] [Abstract][Full Text] [Related]
15. Factor VIII moiety of recombinant Factor VIII Fc fusion protein impacts Fc effector function and CD16
Lagassé HAD; Ou J; Sauna ZE; Golding B
Front Immunol; 2024; 15():1341013. PubMed ID: 38655263
[TBL] [Abstract][Full Text] [Related]
16. Recombinant factor IX Fc fusion protein in children with haemophilia B (Kids B-LONG): results from a multicentre, non-randomised phase 3 study.
Fischer K; Kulkarni R; Nolan B; Mahlangu J; Rangarajan S; Gambino G; Diao L; Ramirez-Santiago A; Pierce GF; Allen G
Lancet Haematol; 2017 Feb; 4(2):e75-e82. PubMed ID: 28159192
[TBL] [Abstract][Full Text] [Related]
17. Single centre, real-world experience of perioperative rFIXFc use in adult patients with haemophilia B undergoing major and minor surgery.
O'Donovan M; Singleton E; Roche S; McGowan M; Benson J; Bergin C; Bird R; Byrne M; Duggan C; Gilmore R; Ryan K; Dougall A; O'Donnell JS; O'Connell NM
Haemophilia; 2021 Nov; 27(6):e690-e697. PubMed ID: 34614282
[TBL] [Abstract][Full Text] [Related]
18. Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients.
Shapiro AD; Ragni MV; Valentino LA; Key NS; Josephson NC; Powell JS; Cheng G; Thompson AR; Goyal J; Tubridy KL; Peters RT; Dumont JA; Euwart D; Li L; Hallén B; Gozzi P; Bitonti AJ; Jiang H; Luk A; Pierce GF
Blood; 2012 Jan; 119(3):666-72. PubMed ID: 22110246
[TBL] [Abstract][Full Text] [Related]
19. Extending recombinant factor IX Fc fusion protein dosing interval to 14 or more days in patients with hemophilia B.
Shapiro AD; Pasi KJ; Ozelo MC; Kulkarni R; Barnowski C; Winding B; Szamosi J; Lethagen S
Res Pract Thromb Haemost; 2019 Jan; 3(1):109-113. PubMed ID: 30656283
[TBL] [Abstract][Full Text] [Related]
20. Predicting the outcomes of using longer-acting prophylactic factor VIII to treat people with severe hemophilia A: a hypothetical decision analysis.
Miners AH; Krishnan S; Pasi KJ
J Thromb Haemost; 2016 Nov; 14(11):2141-2147. PubMed ID: 27510890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
